Mefloquine (also known by the trade name Lariam) is an anti-malarial drug that has been in use for over thirty years and is on the World Health Organisation’s List of Essential Medicines. It is the primary anti-malarial drug prescribed to members of the armed forces in the UK, but recent controversy about psychiatric side effects have led some to call for it to be replaced with a different anti-malarial treatment.
While potential psychiatric side effects from mefloquine use have been documented for many years, the extent to which psychiatric issues in the armed forces may be due to the drugs is complicated and unclear due to the elevated risk of certain psychiatric conditions within this group.
The Ministry of Defence has opened into an inquiry into the use of mefloquine in the armed forces, and is currently hearing evidence from various experts and individuals. Journalists came to the SMC to hear three scientists discuss the evidence and issues around mefloquine use and mental health in the armed forces, and answer questions such as:
Speakers:
Dr Ron Behrens, Senior Lecturer in Tropical and Travel Medicine at the London School of Hygiene & Tropical Medicine, & Consultant in Tropical and Travel Medicine, Hospital for Tropical Diseases, University College NHS Foundation Trust
Prof Neil Greenberg, Professor of Defence Mental Health, Academic Centre for Defence Mental Health, King’s College London